American Scientific Resources to acquire the intellectual property of Disintegrator home needle destruction device

October 12, 2015

???The changes we have made to the format and frequency of our long-standing Roper study were the direct result of consultation with our Western European clients,??? said Ian Pike, director of GfK Healthcare??�s Roper Global Diabetes Group based in the United Kingdom. ???Traditionally, our study mainly provided strategic insights, but now, with the level of detail gleaned from the separate waves covering each of the patient groups, the study provides more utility and supports the ability for diabetes marketers to address tactical issues among patients.???

About the Roper Global Diabetes Programme

GfK Healthcare??�s Roper Global Diabetes Programme includes a series of multiclient tracking studies with diabetes patients conducted annually in the United States, Canada and Western Europe, as well as periodic studies in Eastern Europe, Latin America and Asia Pacific. The 2009/2010 Roper Western Europe Diabetes Patient Study provides key information on every facet of diabetes, from patient attitudes and demographics to product usage, to source of care and the doctor/patient relationship. The study, to be fielded in six monthly waves across five European countries from October 2009 through March 2010, will be conducted via phone interviews with a sample of 1,500 diagnosed diabetes patients for the three random sample waves (months 1, 3, 5) and with a sample of 500 patients for each of the three niche target group waves (months 2, 4, 6).